Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

Gilead Submits NDA for HIV Combo Therapy & More New Antibiotics Show Positive Results in Trials: Business Watch Report

JUN 15, 2017 | CONTAGION® EDITORIAL STAFF

Spero Therapeutics Shows Scientific Momentum at ASM Microbe Annual Meeting 

Spero Therapeutics recently presented 21 posters at ASM Microbe 2017 on new data supporting the ongoing clinical development program of the Company’s lead Potentiator candidate, SPR741, and the Company’s third drug candidate, SPR720. Research presented showed that SPR741, which is being studied in Gram-negative bacteria, significantly lowers the doses of co-administered antibiotics needed to stop bacterial growth. Posters focusing on SPR720 showed that the drug candidate was effective at reducing the level of bacteria present in both the tuberculosis (TB) and the non-tuberculous mycobacteria (NTM) lung disease models. To view the posters, please visit the Spero website here.
 

Clorox Healthcare Announces New Product Enhancements and Compatibility Resources 

Clorox Healthcare announced important enhancements to two leading healthcare disinfectants at the APIC 2017 annual conference. Reformulated Clorox Healthcare® Hydrogen Peroxide Cleaner Disinfectants and Clorox Healthcare® Bleach Germicidal Wipes continue to offer the same powerful disinfection efficacy that hospitals trust, now with improved surface compatibility and visibly less residue. Also introduced was Clorox Healthcare Compatible, a new resource to help facilities identify disinfecting solutions compatible with the surfaces commonly found in healthcare settings and help manufacturers ensure their products align with essential infection prevention protocols. Through the program, Clorox Healthcare works with manufacturers to provide complementary screening of a broad platform of chemistries, compatibility expertise and access to a third-party lab for testing to help ensure the disinfecting products used to reduce the risk of HAIs won’t damage surfaces and equipment.
 

TECHLAB Receives FDA 510(K) Clearance to Market E. HISTOLYTICA QUIK CHEKTest 

TECHLAB, Inc. announced that it received FDA clearance for E. HISTOLYTICA QUIK CHEK™ test. E. HISTOLYTICA QUIK CHEK ™ test is the only rapid diagnostic test that specifically detects pathogenic E. histolytica and does not cross react with non-pathogenic Entamoeba dispar.  E. HISTOLYTICA QUIK CHEK™ test can be paired with the GIARDIA/CRYPTOSPORIDIUM QUIK CHEK™ test to provide a complete triple parasite screen.  E. histolytica is morphologically identical to a non-pathogenic species, E. dispar, making accurate diagnosis very difficult. Other currently available tests and microscopy cannot differentiate between the two species, frequently resulting in an inaccurate diagnosis.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


Want more information on this topic and the opportunity to ask questions of an expert? Register for a live, ACPE accredited webinar February 28th 8-9 PM EST at this link: https://www.pharmacytimes.org/live-events/1106
FEATURED
Big advances in treatment can